Foamix stock: buy or sell?
February 24th, 2020
Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations primarily for the treatment of moderate-to-severe acne, moderate-to-severe papulo-pustular, rosacea, and other skin conditions in the United States, Germany, and France.
Should I buy Foamix stock?Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. Following a trading plan helps to make decisions easier, quicker and with less hesitations. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
None of our preferred buy setups matches with Foamix stock situation right now, hence this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Foamix Pharmaceuticals stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.Unfortunately, we couldn't find any rating for FOMX stock for the last 30 days.
Foamix stock analysis
Foamix Pharmaceuticals closed today at $4.03 and collapsed a hair-raising -7.57%.
Foamix collapsed a hair-raising -7.57% and closed at $4.03. Since price and SMA200d lines crossed up on December, FOMX climbed $1.11 (38.01%). Since SMA100d and SMA200d crossed up on December, FOMX price climbed $1.26 per share (45.49%).
Shares of Foamix closed this week at $4.03 and collapsed a hair-raising -7.57%. Early February FOMX skyrocketed an amazing 14.44% in just one week. This was the 3rd red week in a row, sliding in full a -12.21%.
Observing the weekly chart, FOMX marked an uptrend of rising tops and rising bottoms. Since its last top by mid January at $4.84, price slid and bounced up back from $3.74. Breaking down under $3.74 would cancel the current uptrend and it might test lower supports. Note that $4.84 might act as a resistance line. By mid December 2019 FOMX price bounced up over the SMA of 40 weeks that acted as support stopping new slides. Early December, SMA20w and SMA40w crossed up triggering a rise of 26.73%.
Foamix stock price history
Foamix IPO was on September 18th, 2014 at $8.00 per share1. Since then, FOMX stock sliced a -49.60%, with a yearly average of -9.90%.
1: Adjusted price after possible price splits or reverse-splits.
Foamix stock historical price chart
FOMX stock reached 52-week highs on Jan/16 at $4.84, and all-time highs 2015-05-27 with a price of 14.
Foamix stock price targetPredicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. You should not follow the analysts' FOMX stock price predictions in the hope that they will be met as they may be wrong and not met. For the last month we have not detected any price prediction for Foamix Pharmaceuticals stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per Share, Foamix presented its financial report, posting a super good climb for the Earnings per Share (EPS). Experts were expecting $-0.26 per share, but Foamix posted $-0.39.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Foamix Pharmaceuticals annual revenues declined an unpleasant -2.02% to $3.60 M USD from $3.67 marked in 2017. When comparing 2018 vs 2017, in contrast, profit margin (that is, the net income divided by revenues) collapsed a -271.86% to -2,062.95%.
|2013||$1.40 M||-||$-2.43 M-173.6%||-|
|2014||$5.41 M||286.71%||$-11.48 M-212.1%||372.59%|
|2015||$0.85 M||-84.32%||$-16.52 M-1945.5%||43.83%|
|2016||$5.53 M||551.00%||$-29.34 M-530.8%||77.61%|
|2017||$3.67 M||-33.62%||$-65.72 M-1791.1%||124.01%|
|2018||$3.60 M||-2.02%||$-74.16 M-2062.9%||12.86%|
Quarterly financial resultsFoamix Pharmaceuticals reported $0.86 M in revenues for 2018-Q4, a -0.58% decline compared to previous quarter. Reported quarter income marked $-14.08 M with a profit margin of -1,636.98%. Profit margin skyrocketed a 152.62% compared to previous quarter when profit margin was -1,789.60%. When comparing sales to same quarter last year, Foamix sales marked a scary decrease and plummed a -17.55%. Looking back to recent quarterly results, Foamix Pharmaceuticals posted 2 positive quarters in a row.
|2017-Q1||$0.93 M||-||$-14.38 M-1551.2%||-|
|2017-Q2||$0.80 M||-13.92%||$-16.39 M-2053.9%||13.98%|
|2017-Q3||$0.90 M||12.91%||$17.58 M1951.5%||-207.28%|
|2017-Q4||$1.04 M||15.76%||$-17.36 M-1664.5%||-198.74%|
|2018-Q1||$0.91 M||-13.14%||$-25.98 M-2867.2%||49.63%|
|2018-Q2||$0.96 M||6.40%||$-18.63 M-1932.4%||-28.29%|
|2018-Q3||$0.87 M||-10.27%||$-15.48 M-1789.6%||-16.90%|
|2018-Q4||$0.86 M||-0.58%||$-14.08 M-1637.0%||-9.06%|
Foamix ownershipWhen you are planning to buy shares of a company, it's worth to have a look its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Foamix Pharmaceuticals, 1.12% of all outstanding shares are owned by its staff.
In case of Foamix stock, 49.79% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for FOMX stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Foamix Pharmaceuticals:
|Market cap||$246.8 M|
|Total shares||61.3 M|
|Float shares||46.2 M|
|- Institutional holdings (%)||49.8%|
|- Insider holdings (%)||1.1%|
|Shares in short selling||0.0%|
|Monday, February 24th, 2020|
|Day range||$4.01 - $4.24|
|Average true range||$0.24|
|50d mov avg||$3.87|
|100d mov avg||$3.53|
|200d mov avg||$3.13|
Foamix performancePerformance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. For Foamix Pharmaceuticals, the comparison is made against .